- The UK National Screening Committee (UKNSC) has advised against routine prostate cancer screening for most men, concluding that the PSA test is "likely to cause more harm than good."
- This decision stems from concerns about overdiagnosis and the potential for treatment side effects, such as incontinence and erectile dysfunction, in men who may not require intervention.
- An exception has been made for men with BRCA2 genetic mutations and a family history of certain cancers, who are now recommended for screening every two years between the ages of 45 and 61.
- The UKNSC also advised against screening for other high-risk groups, including black men and those with BRCA1 mutations, citing insufficient evidence or lower risk.
- While Cancer Research UK supports the evidence-based recommendation, Prostate Cancer UK expressed deep disappointment, arguing that a mass screening programme could save thousands of lives.
IN FULL
